There is considerable interest in the exploitation of microbial biological control agents (MBCAs) for the control of crop pests, weeds and diseases. MBCAs can be used where chemical pesticides are banned or being phased out or where pests have developed resistance to standard chemicals.
Introduction
Biopesticides, by the general definition, are pest limiting agents of biological origin which include microbial living systems (bacteria, fungi, viruses), entomopathogenic nematodes, insect predators and natural parasites, plant derived products (botanicals) and insect pheromones (natural and semiochemicals) [1, 2] . Under United States Environmental Protection Agency (US EPA) regulation, the use of plant incorporated protectants (such as Bacillus thuringiensis (Bt)-toxins in transgenic plants), genetically engineered micro-organisms, biochemical compounds with a non-toxic mode of action and biochemical like compounds appropriate for reduced data are also considered biopesticides [3] . Given the large number of biopesticide products [4] , this review can cover only a fraction of this large group and refers to microbial pesticides or microbial biological control agents (MBCAs). Products containing bacteria, fungi or viruses are currently receiving a lot of attention from researchers, industry and authorities [2, 5, 6] .
In 1996, the predicted market size for biocontrol products for the year 2000 was 10% of all pesticides sold around the world, with a value of $3 billion [7] . Today, the world pesticide market is estimated at $25 billion, but only 1% ($300 million) is spent on biopesticides. In the European Union (EU), the total pesticide market is estimated at $5 billion with 2% of this total volume being biopesticides ($100 million). Of this $100 million only 25% comes from sale of MBCAs. The largest proportion of these MBCAs are Bt products with 80-90% of the market and only $2.5-5 million comes from non Bt-sales [2] . Despite the fact that scientists have been working for over 50 years on biological control and integrated pest management (IPM) systems, the biocontrol business is growing a rate of only 10% per year [8] . Consequently, only a few decent medium-sized companies make a profit selling biological products. Most biopesticide companies are unprofitable or marginally profitable [9] .
Perceptions of MBCAs
There are three major unique features of MBCAs which make them of interest to a farmer: (i) resistance management (ii) restricted entry intervals and (iii) residues. Because most MBCAs have multiple modes of action [10, 11] there is less chance of resistance developing in a particular pathogen, insect or weed. Therefore, MBCAs are an excellent tool in IPM programmes, where synergistic effects can be utilized to reduce the input of chemicals or to re-establish efficacy [6, 12] . The majority of MBCAs if not all have low restricted entry intervals, normally in the range of 0-4 h [9] . In addition, they generally have no pre-harvest interval, which essentially allows the farmer to harvest a crop directly after an MBCA has been applied. Finally, MBCAs are generally considered exempt from tolerances (maximum residue limits) under US EPA regulation. The US EPA considers these products safe and therefore that residues on leaves and fruit do not pose an unacceptable risk [9] . Under EU regulation, residue data are not relevant only if no adverse effects are identified from the proposed use. Residues are here considered as toxins produced by micro-organisms that may be of biological significance. If produced by a micro-organism, maximum residue levels (MRLs) have to be established for these toxins.
MCBAs in the EU, US and Canada
Despite progress made in research and development associated with the use of MBCAs, the use of these products in the EU is still very limited. As demonstrated in Tables 1a, b , c and 2, the number of products registered in the EU in comparison with other countries (e.g. the US) is very small. Tables 1a, b and c list 68 MCBAs used as bactericides, fungicides, herbicides, insecticides and nematicides that fulfill at least one of the following requirements: (1) registration as an active substance in the US; (2) registration as an active substance in Canada; (3) registration as an active substance in an Organization for Economic Co-operation and Development (OECD) member state outside the EU; (4) registration in an EU member state as an 'old active' substance or with a provisional registration; (5) inclusion of the active substance in Annex I of Directive 91/414/EEC; (6) under evaluation as a 'list 4' substance as either a 'new existing' or an 'old active' substance. In order to limit the list to a reasonable length Bt and insect virus products are not listed in detail. The Bt group alone represents 13 active ingredients in 106 products on the US market only [17] . A detailed list of products containing Bt or viruses as active substances can be found elsewhere [18, 19] (Table 1a and b). The main reason for the difference in the number of products registered lies in the regulatory system that applies to microbial plant protection products in the EU.
Regulation of MBCAs in the US, Canada and the EU
The US regulatory requirements for microbial pest control products are outlined in Microbial Pesticide Data Tables 40 CFR 158.740 established in 1988. However, US EPA recently proposed a change in data requirements for biochemical and microbial pesticides, taking into account that the current regulation was established 24 years ago and therefore data requirements needed adjustment [20] . In Canada, the Pest Management Regulatory Agency (PMRA) establishes the data requirements for microbial pest control products which are outlined in Regulatory Directive DIR2001-02. In the EU, the placing of plant protection products on the market is regulated by Council Directive 91/414/EEC. Plant protection products containing micro-organisms as active substances are submitted to this directive, which has been modified by Commission Directive 2001/36/EEC to specify requirements for micro-organisms.
The main differences between the regulatory systems in the US, Canada and EU are not within the overall data requirements. They are quite similar, but in the US and Canada, the description of the data requirements is more Sclerotinia spp.
Fusarium wilt diseases
Damping-off and soil-borne fungal diseases (Tables 1a, b and c) .
With respect to the risk assessment, the evaluation in the US and Canada is based on a maximum hazard testing and not provided by the applicant. Conversely, in the EU, risk is evaluated on a hazardÂexposure basis and the applicant has to provide the risk assessment for the MBCA in the dossier submitted to the authorities.
One of the major differences between the EU regulations and those of other countries lies in the requirement by the EU to provide efficacy data for the MBCA for all intended specific uses in specific crops [10] . Therefore, a product has to be evaluated in several experiments, in different geographic zones and for two consecutive years. As a consequence, products that have registrations for use on multiple crops against several diseases in the US will have a registration in the EU for a specific use only [10] . In the EU, this approach is used to prevent the application of products with no efficacy but potential unwanted side effects. Conversely, US EPA does not require efficacy data, because the attitude is that the market should decide whether a product is accepted by farmers or not. As a consequence, several products are currently registered with US EPA, but are not sold in significant quantities.
Additional Reasons for the Low Number of Products Registered in the EU versus US and Canada
As described above, the registration process is the main hurdle to overcome in the successful commercialization of an MBCA. There are some major problems within the regulatory process that are responsible for the delays in registration ( Table 2 ). The guidelines currently used to evaluate MBCAs were originally developed for chemical pesticides and are mostly not appropriate for microorganisms [23] . In some cases (e.g. sensitization properties), authorities have recognized that methods for testing dermal sensitization are not suitable for testing microorganisms. Sensitization by inhalation is considered to be most probably a greater problem than dermal exposure, but no validated test methods are available [24] . As a consequence, all micro-organisms are regarded as potential sensitizers. This presumptive safety approach also takes into consideration immuno-compromised or other sensitive individuals in the population [24] . However, as a consequence, the formulated product carries an Xn-label which indicates that the content is classified as a sensitizer (R42/R43). From the standpoint of commercialization, this safety precaution has a tremendous impact on the handling, shipping and storage of a product that supposedly is a safe alternative to chemical pesticides. This definitely contradicts the general perception of biological control products. In addition, products with an Xn-labelling cannot be stored longer with food in cold storage and the shipping and handling costs are significantly increased because a dangerous good is shipped. Consequently, the end user price increases, which makes an MBCA less attractive to the farmer and the product is no longer considered as safe by the end user [21] . The question whether toxins produced by microorganisms pose a risk to workers and consumers has fuelled the discussions on the safety of biocontrol agents in past years. Two EU funded Research, Technological Development (RTD)-projects, BIPESCO (Biological Control of Soil Dwelling Pests, FAIR6-CT989-4105) and RAFBCA (Risk Assessment of Fungal Biocontrol Agents, QLK1-2001-01391), were initiated to enhance the production, formulation, and efficacy of fungal biocontrol agents and evaluate the risks involved with the application of these MBCAs [25] . One of the major concerns during the registration process of an MBCA, the production of metabolites, or toxins, was intensively investigated in the RAFBCA project. The objectives of the project were to identify and characterize metabolites produced by fungal BCAs, and to establish whether they entered the food chain and posed a risk to human and animal health based on new risk assessment tools. The major outcome of this research was that the potential for exposure to metabolites produced by certain fungal MPCAs was considered to be low [26] [27] [28] [29] (for more details see www. rafbca.com).
Changes in the Requirements for the Development of an MBCA
The development of an MBCA requires several steps. However, the importance of each step and the impact of a single step on the whole process of discovering, developing and commercializing an MBCA has certainly changed over the last decade. This is especially true for EU member states and in part also for the US and Canada. Ten years ago, the strategies for selecting and developing microbial biopesticides for the control of insect weeds and plant pathogens focussed on technological constraints [30] .These technological constraints included the lack of low-cost production methods, stable formulations with reasonable shelf-lives and efficacy under field conditions. Strategies for selecting potential biocontrol agents and experimental approaches to overcome the constraints were of key importance at that time. National registrations of formulated product Figure 1 Basic procedures for the development and commercialization of a microbial biocontrol agent (a) general scheme modified after Montesinos [31] and (b) scheme demonstrating the requirements under current EU regulation [31] , placed emphasis on the initial steps of isolation, identification and characterization (Figure 1a) . Until a few years ago, these first steps were rather laborious and resource intensive with a maximum success rate of 1% or less. Due to the advances in understanding the mechanisms involved and responsible for biocontrol activity, nowadays selection of potential biocontrol agents can be based on certain traits that are responsible for biocontrol efficacy [32] . Therefore, potential organisms can be selected at an early stage for further testing with an increased success rate [32] . Initial trials with the candidate strains are done under a range of conditions to fully evaluate their potential for disease control. In the new scheme (Figure 1b) this phase is of great importance for commercial and regulatory reasons [33] . At this point, the researcher should identify potential crops and cropping systems and determine effects such as physical, chemical or cultural factors that limit the effectiveness of the MBCA. Furthermore, in the context of regulatory issues, application timing and rates as well as pathogen thresholds have to be established early on in the development process.
Once a candidate strain has been selected for further development, a decision on patenting has to be made. Patenting is particularly important for researchers who want to later licence their invention to a company. However, costs for obtaining and maintaining patents are high and although large number of patents on the use of MCBAs have been filed, only a fraction has materialized into registrations of the active substance [31] . This indicates that factors other than patents are more important for success in developing and commercializing MBCAs.
Major improvements have been made in recent years in the process of mass production and formulation of microorganisms. The development and improvement of solid state fermentation technologies for filamentous fungi [34, 35] has led to the development of several new MBCAs. The advantages of solid state fermentation such as low capital investments and energy requirements combined with cheap and simple media have reduced the production costs to a level competitive with chemical pesticides [36, 37] . Furthermore, the development of new formulations of MBCAs have led to better storage stability, compatibility with standard application equipment and increased efficacy [13, 37] . The advances in the fermentation and formulation process have also led to an increase in the quality of biocontrol products. The possibility of contaminants (unwanted pathogens, toxins or toxic metabolites) in a biocontrol product needs to be considered at an early stage of development [38] .
Field studies to evaluate the efficacy of the candidate organism must be conducted before an MBCA can be considered seriously for further development. Evaluation of product efficacy under diverse practical conditions can help to identify the limits of the MBCA. Furthermore, a compatibility profile of the MBCA with other crop protection inputs is essential for successful commercialization [39] . Lack of consistency in efficacy of biological products is still a problem [10] . However, a recent metadata analysis of efficacy data for MBCAs by Oijambo and Scherm [40] revealed that some of the previous assumptions concerning the efficacy of biocontrol products are not correct. Their study revealed a moderate effectiveness on average, but no differences between the effects of biocontrol agents in greenhouse versus field studies, between the effects on soil-borne versus aerial diseases, or under conditions of low, medium and high disease pressure. However, effects were greater on annual than on perennial crops, but were not different for fungal versus bacterial biocontrol agents or for those targeting fungal or bacterial pathogens. Interestingly, on average the efficacy of Bacillus spp. was lower than that of other antagonists. Finally, the effect of one or two sprays for control of aerial diseases was significantly greater than the application of eight sprays or more; this indicates that in an attempt to compensate for anticipated poor performance of biocontrol agents, more applications than necessary are made [40] .
Recent developments in application technologies for MBCAs were reviewed by Gan-Mor and Matthews [41] who found several improvements in application technologies for biopesticides but concluded that yet more research and development is needed to make sure that promising products can be applied by farmers. Furthermore, advances in downstream processing and formulations of MBCAs, such as Bt and viruses, which have been in use for decades, allow further significant improvements in economy, shelf-life, ease of application and field efficacy [19, 42] . By improving production and formulation of these products even wider use can be expected in the future.
In Figure 1a , the registration process is considered of equal importance to all other steps in the process of developing and commercializing an MBCA. Conversely, under the current EU regulatory system, several major hurdles have to be negotiated before the successful registration of a biocontrol agent (Figure 1b) . Toxicological and environmental impacts are amongst the key issues in the current discussions concerning the registration process for MBCAs in the EU [25, 43, 44] . Better knowledge of the fate and behaviour of an introduced micro-organism in the environment is also crucial for appropriate assessment of potential side effects. It is desirable that the biocontrol agent is established in the area to which it is applied only for the period necessary for the control of the pathogen or pest in order to minimize risks that may ensue from its application. Longer persistence would increase exposure and the possibility of unwanted side effects [44] .
MBCAs represent a complex array of approaches towards pest control. Their use for pest control presents challenges in understanding target selectivity, and the occurrence and fate of MBCAs in the environment [45] . Therefore, careful testing of human health risks http://www.cababstractsplus.org/cabreviews posed by the biocontrol agents is necessary [46] . However, experiences so far do not suggest an unreasonable risk of adverse health effects associated with MBCAs although the possibility of infectious and immunological responses needs consideration in the context of human exposure [45] .
Guidelines that can be used to appropriately address the risks involved in using an MBCA are still lacking. More research is needed on the development of test systems and guidelines to adequately measure the risk a microorganism poses to the environment [47] . The methodology developed by Van Lenteren et al. [48] to assess the risks of import and release of exotic enemies used in inundative forms of biological control cannot be extrapolated for MBCAs [47, 49] . Längle [50] further developed the model that integrates information on the potential of an organism to establish and disperse, its host range and possible direct and indirect effects on nontarget organisms, to better fit the needs for MBCA risk assessment.
All the above mentioned requirements for MBCAs have significantly contributed to the increase in the costs for obtaining a registration. A decade ago, the costs for registration of an MBCA were estimated at $200 000-500 000 in the US and Canada with a total of $1-2 million for its development, registration and commercialization [11, 51] . However, more recent estimates were in the range of $500 000 to 1 million for the EPA registration process [9] . Moreover, the costs for obtaining a registration in a single EU member state for on a specific crop can reach $300 000 [37] . Krause et al. [33] calculated that based on the current EU registration requirements an investment of $7-9 million over the course of 6-10 years is needed for registering and commercializing a new MBCA in the EU. Therefore, before a decision is taken on the commercialization of biocontrol product a thorough market analysis is necessary. The development should be market-and not product-driven to avoid failure and ensure that a return on investment is possible within the first three years after sales have begun [7] .
Outlook
Although almost all the companies that undertook registrations of the products listed in (Table 2 ) have currently suspended their research and development efforts for new biocontrol agents, there are still many reasons for being optimistic. There are several initiatives underway that will help to promote the use of biocontrol products in the future. Concerning efficacy, a certification scheme was developed that provides a farmer with data on the efficacy of an MBCA to counteract the impression of 'snake oil': products that are sold as biopesticides but without proof of efficacy [6] . From the regulators side there have been new initiatives to promote the use of alternative products. The Pesticide Safety Directorate (PSD) in the UK has launched a new biopesticide scheme to facilitate more alternative products entering the market. Key elements are the appointment of a 'Biopesticide Champion', an expert providing the initial contact to help applicants through the application process. Secondly, specific guidance to applicants is provided via pre-submission meetings. Thirdly, the cost of evaluations, which has been one of the main concerns for applicants, has been reduced [21] (for more details see www.pesticides.gov.uk). Currently, the EU funded specific support action, acronym 'REBECA' (Regulation of Biocontrol Agents), is underway with the objective of bringing together stakeholders from industry, science, regulatory authorities, policy and environment to form a network of expertise within the EU (for more details see www.rebeca-net.de). This expertise should help to improve regulatory procedures for MBCAs [52] . With this in mind, the use of MBCAs can play an important role in future crop protection, as a key element in IPM programmes.
